Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

Cancer research · Endometrial cancer

Overall survival was a secondary endpoint and PFS per RECIST v.1.1 by blinded independent central review was an exploratory endpoint.

In the phase 3 NRG GY018 study, pembrolizumab plus chemotherapy significantly improved investigator‑assessed progression‑free survival (PFS; primary endpoint) versus placebo plus chemotherapy in patients with advanced/metastatic/recurrent endometrial cancer regardless of mismatch repair status. Overall survival was a secondary endpoint and PFS per RECIST v.1.1 by blinded independent central review was an exploratory endpoint.

The study evaluates whether adding pembrolizumab to standard chemotherapy improves survival outcomes in advanced or recurrent endometrial cancer, informing first‑line treatment decisions irrespective of mismatch repair status.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals